Myelofibrosis

March 27th 2025

Interim results from an observational trial of patients with myelofibrosis indicate upward trends in health-related quality of life when started on the highest tolerable dose of ruxolitinib.

March 26th 2025

Using Janus kinase inhibitors, having experienced a previous thrombosis episode, and higher age were associated with a heightened risk of a new thromboembolic event.

March 20th 2025

Allogeneic stem cell transplant (allo-SCT) conditioning with busulfan/fludarabine with thiotepa and posttransplant cyclophosphamide induced improved 2-year progression-free survival and overall survival in patients with myelofibrosis, especially older adults.

March 16th 2025

Treatment with ruxolitinib in patients with myelofibrosis and anemia was associated with more inpatient medical center and emergency department visits while increasing health care-related financial burdens compared with nonanemic patients.